Literature DB >> 12222670

Clinical trials with hypericum extracts in patients with depression--results, comparisons, conclusions for therapy with antidepressant drugs.

Volker Schulz1.   

Abstract

By the spring of 2002, results from 34 controlled, double-blind trials of Hypericum extracts in some 3000 patients, predominantly with mild to moderate forms of depression, had been published. An overview is given of the studies conducted since 1990. In the majority of them, the efficacy criterion (primary endpoint) was the score and/or response rate on the Hamilton Rating Scale of Depression (HAMD). In ten studies, based on extracts prepared with 50% or 60% ethanol in water (V/V), the dosages ranged from 300 mg to 1050 mg of extract per day. Five of the ten studies were placebo-controlled and in all five cases, the Hypericum extract was shown to be significantly superior. Results with Hypericum were as good or even better than with imipramine or fluoxetine. In the period since 1990, a total of twelve controlled trials have been published with one particular extract prepared with 80% methanol in water (V/V), of which six were placebo-controlled, two compared Hypericum with imipramine and one each with maprotiline, amitriptyline, sertraline or light therapy. Dosages ranged from 450-1200 mg extract per day. Statistical analysis of the total Hamilton scores showed significant differences between Hypericum extract and placebo in four of the six placebo-controlled studies and a trend in favour of the active treatment in the other two. Of the five comparative trials against four different synthetic antidepressants, amitriptyline was significantly superior to Hypericum after six weeks of therapy, whilst there were no significant differences in treatment outcome between Hypericum and the other synthetics in the remaining four studies. The results of the trials conducted to date show no major differences in efficacy of the alcoholic extracts. Taking all the results into account, it can be assumed that the threshold dose for efficacy against individual symptoms and complaints that occur in the course of the depressive illness could be about 300 mg of extract per day. In the medically supervised treatment of mild to moderate depression, doses of approximately 500-1000 mg of extract per day of these preparations of St. John's Wort are of comparable efficacy to synthetic antidepressants in their normally prescribed dosages.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12222670     DOI: 10.1078/09447110260571742

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  8 in total

1.  Effects of St John's wort (Hypericum perforatum L.) extracts on epileptogenesis.

Authors:  Vesna Ivetic; Svetlana Trivic; Marija Knezevic Pogancev; Mira Popovic; Janka Zlinská
Journal:  Molecules       Date:  2011-09-19       Impact factor: 4.411

2.  A randomized clinical trial of St. John's wort for smoking cessation.

Authors:  Amit Sood; Jon O Ebbert; Kavita Prasad; Ivana T Croghan; Brent Bauer; Darrell R Schroeder
Journal:  J Altern Complement Med       Date:  2010-07       Impact factor: 2.579

3.  Total synthesis and structural revision of biyouyanagin B.

Authors:  K C Nicolaou; Silvano Sanchini; T Robert Wu; David Sarlah
Journal:  Chemistry       Date:  2010-07-12       Impact factor: 5.236

4.  Design, synthesis, and biological evaluation of a biyouyanagin compound library.

Authors:  K C Nicolaou; Silvano Sanchini; David Sarlah; Gang Lu; T Robert Wu; Daniel K Nomura; Benjamin F Cravatt; Beatrice Cubitt; Juan C de la Torre; Ann J Hessell; Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-18       Impact factor: 11.205

5.  St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.

Authors:  Zeping Hu; Xiaoxia Yang; Paul Chi-Liu Ho; Eli Chan; Sui Yung Chan; Congjian Xu; Xiaotian Li; Yi-Zhun Zhu; Wei Duan; Xiao Chen; Min Huang; Hongyuan Yang; Shufeng Zhou
Journal:  Pharm Res       Date:  2005-06-08       Impact factor: 4.200

6.  Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers.

Authors:  Andreas Johne; Elke S Perloff; Steffen Bauer; Jürgen Schmider; Ingrid Mai; Jürgen Brockmöller; Ivar Roots
Journal:  Eur J Clin Pharmacol       Date:  2004-09-15       Impact factor: 2.953

Review 7.  Hyperforin in St. John's wort drug interactions.

Authors:  Rajanikanth Madabushi; Bruno Frank; Bernd Drewelow; Hartmut Derendorf; Veronika Butterweck
Journal:  Eur J Clin Pharmacol       Date:  2006-02-14       Impact factor: 2.953

Review 8.  Clinical relevance of St. John's wort drug interactions revisited.

Authors:  Simon Nicolussi; Jürgen Drewe; Veronika Butterweck; Henriette E Meyer Zu Schwabedissen
Journal:  Br J Pharmacol       Date:  2020-01-17       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.